-

Fusion Pharmaceuticals To Present at The 38th Annual J.P. Morgan Healthcare Conference

HAMILTON, Ontario & BOSTON--(BUSINESS WIRE)--Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced that Chief Executive Officer John Valliant, Ph.D., will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation will take place on Thursday, January 16, 2020 at 11:00am PST.

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments. In preclinical studies, the Company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue. Fusion’s lead program, FPI-1434, is currently in a Phase 1 trial.

With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies. For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.

Contacts

Amanda Cray
Senior Director of Investor Relations & Corporate Communications
617-420-5698
cray@fusionpharma.com

Fusion Pharmaceuticals Inc.


Release Summary
Fusion Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Release Versions

Contacts

Amanda Cray
Senior Director of Investor Relations & Corporate Communications
617-420-5698
cray@fusionpharma.com

More News From Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. as Chief Medical Officer

BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion announced the appointment of James J. O’Leary, M.D., as chief medical officer (CMO)....

Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors

BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors...

Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors

BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors....
Back to Newsroom